Zymeworks signs global license and collaboration with Roche for ZW209
Zymeworks Inc. announced a worldwide license and collaboration agreement with Roche for the trispecific T‑cell engager ZW209. The deal provides Zymeworks a $55 million upfront payment, a $40 million payment when Phase 1b starts, and up to $718 million in development, commercial and sales‑based milestones, giving Roche exclusive rights to develop and commercialize the drug. Roche will fund the Phase 1a trial and lead all subsequent development and worldwide commercialization.
Why it matters
The company’s shares jumped 5.5% in pre‑market trading after the announcement, reflecting investor enthusiasm for the sizable potential cash inflow (up to $813 million). Jefferies raised its price target to $52, citing the transaction as net‑present‑value positive per share.
Key facts
- 1Zymeworks will receive a $55 million upfront payment from Roche. tradingview.com
- 2Roche will pay $40 million when the Phase 1b trial of ZW209 is initiated. tradingview.com
- 3The agreement includes up to $718 million in additional milestone payments. tradingview.com
- 4Roche will fund the Phase 1a monotherapy trial and have exclusive worldwide development and commercialization rights. tradingview.com
- 5The transaction is subject to Hart‑Scott‑Rodino antitrust waiting‑period clearance. tradingview.com
- 6Jefferies raised its Zymeworks price target to $52 from $50 after the deal. investing.com
Summary written by AlphAI AI Desk from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.